Traws Pharma Inc
TRAW1.275USD
+0.025+2.00%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
9.09MMarket Cap
0.01P/E TTM
More Details of Traws Pharma Inc Company
Traws Pharma, Inc. is a clinical stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It integrates antiviral drug development, medical intelligence and regulatory strategy in the treatment of viral diseases. The Cadvancing novel investigational oral small-molecule antiviral agents that have potent activity against difficult to treat or resistant virus strains that threaten human health: bird flu and seasonal influenza, and COVID-19/Long COVID. Its four clinical programs consist of Tivoxavir marboxil, Ratutrelvir (TRX0), Narazaciclib, and Rigosertib. Tivoxavir marboxil is a small-molecule cap-dependent endonuclease inhibitor. Ratutrelvir (TRX01) is an inhibitor of the main protease (also known as 3CL protease) of the SARS-CoV-2 virus. arazaciclib is its oral CDK4-plus inhibitor intended initially to treat breast cancers, endometrial and other cancers. Rigosertib is its second asset in oncology.
Traws Pharma Inc Info
Ticker SymbolTRAW
Company nameTraws Pharma Inc
IPO dateJul 25, 2013
CEODukes (Iain D)
Number of employees7
Security typeOrdinary Share
Fiscal year-endJul 25
Address12 Penns Trail
CityNEWTOWN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code18940
Phone12677593680
Websitehttps://www.trawspharma.com/
Ticker SymbolTRAW
IPO dateJul 25, 2013
CEODukes (Iain D)
Company Executives of Traws Pharma Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Nikolay Savchuk, Ph.D.
Dr. Nikolay Savchuk, Ph.D.
Chief Operating Officer, Director
Chief Operating Officer, Director
251.90K
--
Dr. Iain D. Dukes, Ph.D.
Dr. Iain D. Dukes, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
81.19K
--
Mr. Jack E. Stover, CPA
Mr. Jack E. Stover, CPA
Independent Chairman of the Board
Independent Chairman of the Board
8.00
--
Dr. John Leaman, M.D.
Dr. John Leaman, M.D.
Independent Director
Independent Director
--
--
Dr. C. David Pauza, Ph.D.
Dr. C. David Pauza, Ph.D.
Chief Scientific Officer, Virology
Chief Scientific Officer, Virology
--
--
Dr. Robert Redfield, M.D.
Dr. Robert Redfield, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Charles Parker
Mr. Charles Parker
Chief Financial Officer
Chief Financial Officer
--
--
Ms. M. Teresa Shoemaker
Ms. M. Teresa Shoemaker
Independent Director
Independent Director
--
--
Dr. Werner Cautreels
Dr. Werner Cautreels
Director
Director
--
--
Dr. Trafford Clarke, Ph.D.
Dr. Trafford Clarke, Ph.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Nikolay Savchuk, Ph.D.
Dr. Nikolay Savchuk, Ph.D.
Chief Operating Officer, Director
Chief Operating Officer, Director
251.90K
--
Dr. Iain D. Dukes, Ph.D.
Dr. Iain D. Dukes, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
81.19K
--
Mr. Jack E. Stover, CPA
Mr. Jack E. Stover, CPA
Independent Chairman of the Board
Independent Chairman of the Board
8.00
--
Dr. John Leaman, M.D.
Dr. John Leaman, M.D.
Independent Director
Independent Director
--
--
Dr. C. David Pauza, Ph.D.
Dr. C. David Pauza, Ph.D.
Chief Scientific Officer, Virology
Chief Scientific Officer, Virology
--
--
Dr. Robert Redfield, M.D.
Dr. Robert Redfield, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Symbio
2.73M
0.00%
Relevant data have not been disclosed by the company yet.
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Symbio
2.73M
0.00%
Shareholding Stats
Updated: Thu, Dec 18
Updated: Thu, Dec 18
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Viriom Inc
7.58%
OrbiMed Advisors, LLC
7.58%
Squadron Capital Management LLC
7.40%
Adage Capital Management, L.P.
4.13%
Savchuk (Nikolay)
3.36%
Other
69.96%
Shareholders
Shareholders
Proportion
Viriom Inc
7.58%
OrbiMed Advisors, LLC
7.58%
Squadron Capital Management LLC
7.40%
Adage Capital Management, L.P.
4.13%
Savchuk (Nikolay)
3.36%
Other
69.96%
Shareholder Types
Shareholders
Proportion
Investment Advisor
8.77%
Private Equity
7.58%
Corporation
7.58%
Individual Investor
7.00%
Hedge Fund
4.76%
Investment Advisor/Hedge Fund
2.42%
Venture Capital
0.13%
Research Firm
0.06%
Other
61.70%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
49
1.76M
24.67%
-4.81K
2025Q2
57
2.78M
49.98%
+92.22K
2025Q1
59
3.22M
71.94%
+1.74M
2024Q4
58
1.47M
44.66%
+775.47K
2024Q3
57
942.34K
34.05%
+834.58K
2024Q2
58
213.81K
16.43%
+135.65K
2024Q1
55
74.05K
8.78%
-3.08K
2023Q4
60
70.75K
8.42%
-22.28K
2023Q3
70
76.41K
9.11%
-47.84K
2023Q2
73
78.91K
9.41%
-30.66K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Viriom Inc
605.53K
8.57%
--
--
Apr 28, 2025
OrbiMed Advisors, LLC
605.53K
8.57%
--
--
Jun 30, 2025
Squadron Capital Management LLC
420.50K
5.95%
+420.50K
--
Sep 12, 2025
Adage Capital Management, L.P.
330.00K
4.67%
--
--
Jun 30, 2025
Savchuk (Nikolay)
251.90K
3.57%
+168.68K
+202.70%
Apr 28, 2025
Vestal Point Capital, LP
149.80K
2.12%
-25.20K
-14.40%
Jun 30, 2025
Dukes (Iain D)
81.19K
1.15%
-2.03K
-2.44%
Apr 28, 2025
Cautreels (Werner C)
98.35K
1.39%
-6.00K
-5.75%
Apr 28, 2025
The Vanguard Group, Inc.
13.17K
0.19%
--
--
Jun 30, 2025
Geode Capital Management, L.L.C.
35.73K
0.51%
+2.35K
+7.03%
Jun 30, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Sep 17, 2024
Merger
25→1
Sep 17, 2024
Merger
25→1
Sep 17, 2024
Merger
25→1
Sep 17, 2024
Merger
25→1
May 20, 2021
Merger
15→1
May 20, 2021
Merger
15→1
Date
Type
Ratio
Sep 17, 2024
Merger
25→1
Sep 17, 2024
Merger
25→1
Sep 17, 2024
Merger
25→1
Sep 17, 2024
Merger
25→1
May 20, 2021
Merger
15→1
May 20, 2021
Merger
15→1
May 20, 2021
Merger
15→1
May 20, 2021
Merger
15→1
FAQs
Who are the top five shareholders of Traws Pharma Inc?
The top five shareholders of Traws Pharma Inc are:
Viriom Inc holds 605.53K shares, accounting for 8.57% of the total shares.
OrbiMed Advisors, LLC holds 605.53K shares, accounting for 8.57% of the total shares.
Squadron Capital Management LLC holds 420.50K shares, accounting for 5.95% of the total shares.
Adage Capital Management, L.P. holds 330.00K shares, accounting for 4.67% of the total shares.
Savchuk (Nikolay) holds 251.90K shares, accounting for 3.57% of the total shares.
Viriom Inc holds 605.53K shares, accounting for 8.57% of the total shares.
OrbiMed Advisors, LLC holds 605.53K shares, accounting for 8.57% of the total shares.
Squadron Capital Management LLC holds 420.50K shares, accounting for 5.95% of the total shares.
Adage Capital Management, L.P. holds 330.00K shares, accounting for 4.67% of the total shares.
Savchuk (Nikolay) holds 251.90K shares, accounting for 3.57% of the total shares.
What are the top three shareholder types of Traws Pharma Inc?
The top three shareholder types of Traws Pharma Inc are:
Viriom Inc
OrbiMed Advisors, LLC
Squadron Capital Management LLC
Viriom Inc
OrbiMed Advisors, LLC
Squadron Capital Management LLC
How many institutions hold shares of Traws Pharma Inc (TRAW)?
As of 2025Q3, 49 institutions hold shares of Traws Pharma Inc, with a combined market value of approximately 1.76M, accounting for 24.67% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -25.31%.
What is the biggest source of revenue for Traws Pharma Inc?
In FY2025Q2, the Symbio business generated the highest revenue for Traws Pharma Inc, amounting to 2.73M and accounting for --% of total revenue.
